386 related articles for article (PubMed ID: 33989370)
1. L-Dopa release from mesoporous silica nanoparticles engineered through the concept of drug-structure-directing agents for Parkinson's disease.
Morales V; McConnell J; Pérez-Garnes M; Almendro N; Sanz R; García-Muñoz RA
J Mater Chem B; 2021 May; 9(20):4178-4189. PubMed ID: 33989370
[TBL] [Abstract][Full Text] [Related]
2. Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs.
Li T; Geng T; Md A; Banerjee P; Wang B
Colloids Surf B Biointerfaces; 2019 Apr; 176():185-193. PubMed ID: 30616109
[TBL] [Abstract][Full Text] [Related]
3. Kidney-Protector Lipidic Cilastatin Derivatives as Structure-Directing Agents for the Synthesis of Mesoporous Silica Nanoparticles for Drug Delivery.
Martinez-Erro S; Navas F; Romaní-Cubells E; Fernández-García P; Morales V; Sanz R; García-Muñoz RA
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360733
[TBL] [Abstract][Full Text] [Related]
4. Thermo-responsive mesoporous silica/lipid bilayer hybrid nanoparticles for doxorubicin on-demand delivery and reduced premature release.
Zhang Q; Chen X; Shi H; Dong G; Zhou M; Wang T; Xin H
Colloids Surf B Biointerfaces; 2017 Dec; 160():527-534. PubMed ID: 29024917
[TBL] [Abstract][Full Text] [Related]
5. Hybrid mesoporous silica nanospheres modified by poly (NIPAM-co-AA) for drug delivery.
Zhang K; Zhou D; Wang Z; Zhang Y; He P
Nanotechnology; 2019 Aug; 30(35):355604. PubMed ID: 31071691
[TBL] [Abstract][Full Text] [Related]
6. Classics in chemical neuroscience: levodopa.
Whitfield AC; Moore BT; Daniels RN
ACS Chem Neurosci; 2014 Dec; 5(12):1192-7. PubMed ID: 25270271
[TBL] [Abstract][Full Text] [Related]
7. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
Yan Y; Fu J; Wang T; Lu X
Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
[TBL] [Abstract][Full Text] [Related]
8. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
Zhang Q; Zhao H; Li D; Liu L; Du S
Colloids Surf B Biointerfaces; 2017 Jan; 149():138-145. PubMed ID: 27750088
[TBL] [Abstract][Full Text] [Related]
9. A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis.
Gupta A; Kushwaha SS; Mishra A
Recent Pat Drug Deliv Formul; 2020; 14(2):126-144. PubMed ID: 32928094
[TBL] [Abstract][Full Text] [Related]
10. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Atlas D
CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
[TBL] [Abstract][Full Text] [Related]
11. Dual response to pH and chiral microenvironments for the release of a flurbiprofen-loaded chiral self-assembled mesoporous silica drug delivery system.
Wu L; Gou K; Guo X; Guo Y; Chen M; Hou J; Li S; Li H
Colloids Surf B Biointerfaces; 2021 Mar; 199():111501. PubMed ID: 33338882
[TBL] [Abstract][Full Text] [Related]
12. Hollow Mesoporous Silica Nanoparticles with Extra-Large Mesopores for Enhanced Cancer Vaccine.
Lee JY; Kim MK; Nguyen TL; Kim J
ACS Appl Mater Interfaces; 2020 Aug; 12(31):34658-34666. PubMed ID: 32662625
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of mesoporous silica nanoparticles.
Wu SH; Mou CY; Lin HP
Chem Soc Rev; 2013 May; 42(9):3862-75. PubMed ID: 23403864
[TBL] [Abstract][Full Text] [Related]
14. Mesoporous silica nanoparticles for therapeutic/diagnostic applications.
Jafari S; Derakhshankhah H; Alaei L; Fattahi A; Varnamkhasti BS; Saboury AA
Biomed Pharmacother; 2019 Jan; 109():1100-1111. PubMed ID: 30551360
[TBL] [Abstract][Full Text] [Related]
15. IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease.
Ondo W
Expert Opin Pharmacother; 2014 Oct; 15(14):2081-5. PubMed ID: 25146967
[TBL] [Abstract][Full Text] [Related]
16. Surfactant-assisted controlled release of hydrophobic drugs using anionic surfactant templated mesoporous silica nanoparticles.
Tsai CH; Vivero-Escoto JL; Slowing II; Fang IJ; Trewyn BG; Lin VS
Biomaterials; 2011 Sep; 32(26):6234-44. PubMed ID: 21684000
[TBL] [Abstract][Full Text] [Related]
17. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
Lees AJ; Tolosa E; Olanow CW
Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
[TBL] [Abstract][Full Text] [Related]
18. Preparation of levodopa-loaded crystalsomes through thermally induced crystallization reverses functional deficits in Parkinsonian mice.
Li X; Liu Q; Zhu D; Che Y; Feng X
Biomater Sci; 2019 Mar; 7(4):1623-1631. PubMed ID: 30702723
[TBL] [Abstract][Full Text] [Related]
19. Extra-Large Pore Mesoporous Silica Nanoparticles for Directing in Vivo M2 Macrophage Polarization by Delivering IL-4.
Kwon D; Cha BG; Cho Y; Min J; Park EB; Kang SJ; Kim J
Nano Lett; 2017 May; 17(5):2747-2756. PubMed ID: 28422506
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of mesoporous hollow silica nanospheres using polymeric micelles as template and their application as a drug-delivery carrier.
Sasidharan M; Zenibana H; Nandi M; Bhaumik A; Nakashima K
Dalton Trans; 2013 Oct; 42(37):13381-9. PubMed ID: 23887599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
